Ardelyx (ARDX) Stock Price & Analysis
ARDX Stock Chart & Stats
- Day’s Range
- MXN 56.90 - MXN 56.90
- 52-Week Range
- MXN 56.90 - MXN 138.70
- Previous Close
- MXN 56.90
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 13.45B
- Enterprise Value
- MXN 826.03M
- Total Cash (Recent Filing)
- MXN 285.34M
- Total Debt (Recent Filing)
- MXN 256.34M
- Price to Earnings (P/E)
- ―
- Beta
- 0.27
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 0.61
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Product Revenue Growth
Strong growth across both commercial products demonstrates expanding demand and improving market penetration. Continued prescription and writer gains, particularly for IBSRELA, can support operating leverage and provide a durable base for management’s reaffirmed 2026 revenue targets.
High Gross Margins And Profitability Path
A gross margin above 95% gives Ardelyx substantial contribution potential as product revenue scales. If disciplined expense management continues, the combination of strong margins and narrowing losses could support a credible transition toward profitability in 2027.
Pipeline Expansion
Full enrollment ahead of schedule advances a potentially important expansion of tenapanor beyond IBS-C. Management describes the chronic idiopathic constipation market as significantly larger, so successful results could broaden the company’s addressable market and extend product durability.
Bears Say
Elevated Leverage
Rising leverage reduces financial flexibility while Ardelyx remains unprofitable. A higher debt burden can constrain investment in commercialization and trials, and it increases the consequences if revenue growth slows or the planned profitability milestone is delayed.
Negative Cash Generation
Ardelyx has not yet become consistently self-funding despite improving revenue and a smaller cash burn than in earlier years. Continued negative operating and free cash flow may require tighter spending or additional financing, limiting flexibility during commercialization and pipeline investment.
Payer And Reimbursement Friction
Access barriers can delay or prevent prescriptions even when physicians and patients recognize product value. Persistent prior authorization friction and reimbursement complexity may restrain adoption, while gross-to-net erosion reduces the revenue retained from each prescription and pressures scaling economics.
Ardelyx News
Ardelyx (ARDX) Investors File Securities Lawsuit After 18% Stock Drop Over Alleged Drug Revenue and Payer Disclosures
Ardelyx, Inc. ($ARDX) is facing a federal securities lawsuit after its shares fell sharply when the company cut its full-year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH revenue
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
What is Ardelyx’s market cap?
When is Ardelyx’s upcoming earnings report date?
How were Ardelyx’s earnings last quarter?
Is Ardelyx overvalued?
Does Ardelyx pay dividends?
What is Ardelyx’s EPS estimate?
How many shares outstanding does Ardelyx have?
What happened to Ardelyx’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ardelyx?
What is the TipRanks Smart Score and how is it calculated?
Ardelyx Stock Smart Score
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael G. Raab
- Employees
- 489
- Website
- www.ardelyx.com
- Address
- 400 Fifth Avenue, Waltham, MA, 02451, US
Ardelyx (ARDX) Earnings & Revenues
ARDX Company Deck
ARDX Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by 19% total product revenue growth, 23% IBSRELA growth, strong demand trends, reaffirmed 2026 guidance, improved net loss, $285.3 million of liquidity, and ahead-of-schedule enrollment in the ACCEL Phase III trial. The main challenges were persistent payer friction, complex XPHOZAH reimbursement dynamics, gross-to-net erosion, recent prescription-data volatility, and continued operating investments. Management remained confident in execution and the path to profitability in 2027.
View all MX:ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 14 |
| Technical Analysis | 4 | 1 | 4 |
| Moving Averages | 2 | 0 | 10 |
